Last reviewed · How we verify
Apophedrin (phenylethanolamine)
Apophedrin (generic name: phenylethanolamine) is a phenylethanolamine drug. It is currently in unknown development.
Apophedrin is thought to work by stimulating the release of certain neurotransmitters in the brain.
Apophedrin is a small molecule with a structure similar to catecholamine neurotransmitters such as dopamine, norepinephrine, and epinephrine. Its exact clinical uses are not specified in the provided facts, but it is classified as a trace amine with a β-hydroxylated phenethylamine structure.
At a glance
| Generic name | phenylethanolamine |
|---|---|
| Drug class | phenylethanolamine |
| Therapeutic area | Neuroscience |
| Phase | unknown |
Mechanism of action
Imagine your brain is a busy city, and neurotransmitters are like messengers that help different parts of the city communicate with each other. Apophedrin is believed to help increase the number of these messengers being sent, which can help improve communication between different parts of the brain.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apophedrin CI brief — competitive landscape report
- Apophedrin updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Apophedrin
What is Apophedrin?
How does Apophedrin work?
What is the generic name of Apophedrin?
What drug class is Apophedrin in?
What development phase is Apophedrin in?
Related
- Drug class: All phenylethanolamine drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing